SRR1313147
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.600
- E2F_TARGETS+0.580
- MYC_TARGETS_V1+0.580
- MTORC1_SIGNALING+0.560
- MYC_TARGETS_V2+0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.520
- G2M_CHECKPOINT+0.500
- IL6_JAK_STAT3_SIGNALING+0.420
- ALLOGRAFT_REJECTION+0.410
Top 10 suppressed
- MYOGENESIS-0.230
- UV_RESPONSE_DN-0.100
- TGF_BETA_SIGNALING-0.090
- WNT_BETA_CATENIN_SIGNALING-0.080
- BILE_ACID_METABOLISM-0.060
- KRAS_SIGNALING_DN-0.060
- HEDGEHOG_SIGNALING-0.050
- APICAL_JUNCTION-0.010
- ESTROGEN_RESPONSE_EARLY+0.000
- COAGULATION+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0368 | Med | Medulloblastoma | 0.941 |
| 2 | MDT-AP-3375 | Med | Medulloblastoma | 0.921 |
| 3 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.914 |
| 4 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.906 |
| 5 | SRR6013600 | — | cohortA1 | 0.905 |
| 6 | DRR168585 | — | — | 0.901 |
| 7 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.901 |
| 8 | C3F0BD22-6891-44F0-B023-02FC6EDFA7EB | — | — | 0.900 |
| 9 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.899 |
| 10 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |